久久久精品欧美一区二区三区,国产欧美久久久精品影院,亚洲AV福利天堂一区二区三亚洲欧洲日韩国产AⅤ在线,亚洲成av人在线视,四虎国产精品永久地址99自拍三区一级国产片,亚洲男人的天堂久久无在线观看免费黄视频,亚洲一级特黄大片在线播放,国产成人精品区在线观看

Gene Therapy
Home > Application > Gene Therapy > Adeno-Associated Virus

Adeno-Associated Virus

Adeno-associated virus (AAV) is the most commonly used vector in gene therapy, with a diameter of about 20 nm and no envelope. Its genome is about 4.8 kb in length. AAV does not encode DNA polymerase and relies on host cells or helper viruses to synthesize its own genome, so it cannot replicate autonomously. AAV is quite prevalent in humans and other primates, with 11 known serotypes. In addition, many artificial variants of AAV have been developed to improve the efficiency of AAV as vectors in clinical and research applications. For example, Glybera?, the world's first approved AAV-based product, uses AAV1 to deliver lipoprotein lipase (LPL) to treat patients with LPL deficiency. Luxturna? was approved in 2017 as an AAV2-based treatment for Leber's congenital amaukia, which causes progressive blindness, and Zolgensma? was approved in 2019 as an AAV9-based treatment for spinal muscular atrophy (SMA).

 

There are different platform strategies for the upstream production of AAV, including herpes simplex virus (HSV) infection, insect cell-baculovirus expression vector system, and stable production cell line, but the method based on transient transfection of HEK293 cell by plasmid DNA is currently the mainstream method for the production of clinical materials, which is more flexible and easy to use, with low up-front engineering effort, thus can help to quickly initiate the first-in-human studies. Typical process steps for the production of AAV based on transient transfection include: adherent or suspension culture based cell expansion, plasmid transfection, viral vector production, cell lysis, purification – including clarification, affinity capture chromatography, ion exchange polish chromatography, tangential flow filtration for concentration/diafiltration, final sterile filtration and fill/finish.

 

Adeno-Associated Virus

 

The choice of adherent vs. suspension culture should be comprehensively considered based on the technical capabilities of the platform, the stages, target indications and administration routes, and the expected demand for viral vectors. For large patient population , applications that require systemic administration or higher levels of viral vectors per dose, developing a production strategy based on suspension culture will be more conducive to ensuring the required scale-up capability, and it has been reported that AAV suspension culture production up to 2,000 L has been achieved. The purpose of upstream process development is to explore the optimal conditions for virus production, including improving transfection efficiency and ensuring its consistency under large-scale production conditions by adjusting transfection conditions, and intensifying virus productivity through strategies such as optimizing media formulations, maintain viral infectivity.

 

Although some AAV serotypes will partially secrete virus particles into the cell culture media during the culture process, in order to increase the yield of the virus, the downstream process of AAV starts with mechanical or chemical lysis of cells and DNA fragmentation under closed conditions, Subsequent clarification steps are designed to remove residual large amounts of plasmid DNA as well as host cell contaminants from cell lysis. Filter selection should consider the level of turbidity reduction, high product yield, and ease of scale-up. For the capture of AAV by affinity chromatography, there are currently specific affinity resin for various serotypes. Usually, a single-step affinity capture can achieve high purity. However, in order to ensure the specific level of impurity removal, ion exchange chromatography is generally used in combination as a polishing step. Especially for the challenge of separating empty and full capsids in AAV production, ion-exchange chromatography is currently the most commonly used method at production scale. Empty capsids are considered as in-process impurity by regulators and their percentage needs to be reduced as much as possible and the empty/full capsid ratio controlled to ensure consistency of gene therapy products. Tangential flow filtration aims to concentrate the product and replace it with a suitable buffer system. In view of the small particle size of AAV, MWCO 100kD membrane modules can be selected, while sterile filtration aims to reduce microbial load and meet the required sterility regulatory requirements.


Related Products
Contact Us
  • Tel.: +86 021 6434 0155
  • E-Mail: marketing@duoningbio.com
  • Address: Building 30, No. 1525 Minqiang Road, Songjiang District, Shanghai
Message

Copyright ? Shanghai Duoning Biotechnology Co., Ltd. All Rights Reserved Sitemap | Technical Support: Reanod

WeChat
WeChat

Message-

Duoning Biotechnology

+86 021 6434 0155

国产精品成人一级黄国产黄三级看| 午夜欧美日韩精品久久久| 亚洲夜夜性夜综合久久| 亚洲成在人线a免费日本免费一区香蕉视频| YYY6080韩国三级理论久久| 国产乱女乱子视频在线播放| 人妻少妇乱子伦a片| 国产无遮挡18禁无码麻豆| 国产美女露脸口爆吞精一区二区| 亚洲愉拍99热成人精品热久久| 国产精品乱码高清在线观看| 成全视频免费观看在线下载| 丁香婷婷激情俺也去俺来也| 免费无码av一区二区三区| 蜜臀久久99精品久久久久久| 2021777久久人妻少妇嫩草AV| 夫妻自拍,国产亚洲视频在线播放香蕉| 久久人人做人人妻人人玩精品Au_| 人妻少妇精品无码专区漫画| 欧美日韩天堂一区二区三区| 国产成人精品久久一区二区三区av| 日韩精品无码熟人妻我不卡| 最近日本电影hd免费观看| a一级特黄日本大片s色| 在线人成视频播放午夜福利| 婷婷国产天堂久久综合五月| 精品国产一区二区三区不卡| 亚洲成在人线a免费日本免费一区香蕉视频| 国产在线视频一区二区三区| 99午夜精品一区二区三区| 国产成人欧美日韩在线电影| 精品少妇人妻av无码中文字幕| 亚洲麻豆av无码成人片在线观看| 99精品视频九九精品视频| 国产欧美日韩精品?在线观看| 亚洲国产精品免费无码| 中文字幕一精品亚洲无线一区| 天天爽夜夜爽精品免费久久99热精品| 国精品无码一区二区三区在线蜜臀| 亚洲永久国产一级大片在线观看| 无码一区二区免费波多野播放搜索|